Novo Nordisk, Eli Lilly face scrutiny from EU's drug regulator over GLP-1 safety
Fierce Pharma
JUNE 22, 2023
The EMA is scrutinizing GLP-1s, raising a safety signal about the risk that drugs from Novo Nordisk, Eli Lilly and other companies could cause cancer.
Let's personalize your content